ICA Health sells five Dr. Wilson supplements with website claims that make them unapproved new drugs, FDA says.
What happened
FDA reviewed three websites (www.icahealth.com, www.drwilsons.com, www.adrenalfatigue.org) in July 2021 and found the firm takes orders there for five Dr. Wilson's supplements. The sites described the products as helping with diabetes, blood sugar problems, colds and flu, herpes outbreaks, depression, rheumatoid arthritis and other diseases, which FDA says shows the products are intended as drugs. FDA also says four of the products lack adequate directions for use and are therefore misbranded.
What FDA found
Website claims that the supplements treat or prevent diseases such as diabetes, colds and flu, herpes and depression make the products drugs in FDA's view.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]Because the products are not generally recognized as safe and effective for those uses and FDA has not approved them, they are unapproved new drugs and cannot be sold across state lines.
sections 201(p), 301(d) and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]Good Sugar, Cortisol Stress Reset, BFF and Nat-Stim are meant for diseases a layperson cannot safely diagnose or treat alone, so they cannot carry adequate directions for use and are misbranded.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Shipping these misbranded drugs across state lines violates the Act.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to write back within 15 working days of receiving the letter describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If the work is not finished in that time, the company must explain why and say when it will be done.
Who should pay attention
- supplement brands whose websites carry disease-treatment or symptom-relief claims
- retailers and distributors selling Dr. Wilson's branded supplements
- regulatory reviewers who check website and marketing copy for drug claims
This is a summary. Read the original letter on fda.gov.